Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma

Li,Xiaolong; Zhao,Cui; Hu,Dandan; Yu,Yang; Gao,Jin; Zhao,Wenchuan; Gao,Ming

doi:10.3892/ol.2013.1202

Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma

Authors:
- Xiaolong Li
- Cui Zhao
- Dandan Hu
- Yang Yu
- Jin Gao
- Wenchuan Zhao
- Ming Gao
View Affiliations

Affiliations: Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, School of Medicine and Dentistry, James Cook University, Douglas, Queensland 4878, Australia
Published online on: February 19, 2013 https://doi.org/10.3892/ol.2013.1202
Pages: 1412-1416

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Papillary thyroid carcinoma (PTC) is often clinically multifocal. In this study, the clinicopathological characteristics of a total of 347 PTC patients treated between 2006 and 2007 were investigated in order to assess the risk factors for tumor recurrence in patients with multifocal PTC. Of all the PTC cases reviewed, 35 (10%) were categorized as multifocal PTC. Patients with multifocal PTC were significantly more likely to have extrathyroidal extension, lymph node metastases and disease recurrence (P<0.05). Hemithyroidectomy resulted in a significantly higher incidence of tumor recurrence in patients with ipsilateral multifocal PTC compared with unifocal PTC patients (P<0.01). In conclusion, hemithyroidectomy was associated with tumor recurrence in patients with ipsilateral multifocal PTC but not those with unifocal PTC. Hemithyroidectomy should only be carried out after careful deliberation when involving patients with ipsilateral multifocal PTC.

View Figures

View References

1	Sherman SI: Thyroid carcinoma. Lancet. 361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
2	Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 83:2638–2648. 1998.PubMed/NCBI
3	Caron NR and Clark OH: Well differentiated thyroid cancer. Scand J Surg. 93:261–271. 2004.PubMed/NCBI
4	Scheumann GF, Gimm O, Wegener G, Hundeshagen H and Dralle H: Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 18:559–567. 1994. View Article : Google Scholar : PubMed/NCBI
5	Wang TS, Dubner S, Sznyter LA and Heller KS: Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg. 130:110–113. 2004. View Article : Google Scholar : PubMed/NCBI
6	Chow SM, Law SC, Chan JK, Au SK, Yau S and Lau WH: Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer. 98:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
7	Qubain SW, Nakano S, Baba M, Takao S and Aikou T: Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 131:249–256. 2002. View Article : Google Scholar : PubMed/NCBI
8	Arturi F, Russo D, Giuffrida D, et al: Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab. 82:1638–1641. 1997. View Article : Google Scholar : PubMed/NCBI
9	Wada N, Duh QY, Sugino K, et al: Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 237:399–407. 2003. View Article : Google Scholar : PubMed/NCBI
10	Shattuck TM, Westra WH, Ladenson PW and Arnold A: Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 352:2406–2412. 2005. View Article : Google Scholar : PubMed/NCBI
11	Morris LG and Myssiorek D: Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 200:454–461. 2010. View Article : Google Scholar
12	Giannini R, Ugolini C, Lupi C, et al: The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 92:3511–3516. 2007. View Article : Google Scholar
13	Park SY, Park YJ, Lee YJ, et al: Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer. 107:1831–1838. 2006. View Article : Google Scholar : PubMed/NCBI
14	Hay ID, Thompson GB, Grant CS, et al: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 26:879–885. 2002.PubMed/NCBI
15	Salter KD, Andersen PE, Cohen JI, et al: Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. Arch Otolaryngol Head Neck Surg. 136:692–696. 2010. View Article : Google Scholar : PubMed/NCBI
16	Mazeh H, Samet Y, Hochstein D, et al: Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg. 201:770–775. 2011. View Article : Google Scholar : PubMed/NCBI
17	Shaha AR: Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 114:393–402. 2004. View Article : Google Scholar : PubMed/NCBI
18	Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y and Kawaoi A: Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma: a clinicopathologic study of 105 consecutive patients. Cancer. 70:1585–1590. 1992. View Article : Google Scholar
19	Tscholl-Ducommun J and Hedinger CE: Papillary thyroid carcinomas: morphology and prognosis. Virchows Arch A Pathol Anat Histol. 396:19–39. 1982. View Article : Google Scholar : PubMed/NCBI
20	Hughes CJ, Shaha AR, Shah JP and Loree TR: Impact of lymph node metastases in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 18:127–132. 1996. View Article : Google Scholar : PubMed/NCBI
21	White ML, Gauger PG and Doherty GM: Central lymph node dissection in differentiated thyroid cancer. World J Surg. 31:895–904. 2007. View Article : Google Scholar : PubMed/NCBI
22	Shindo M, Wu JC, Park EE and Tanzella F: The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 132:650–654. 2006. View Article : Google Scholar : PubMed/NCBI
23	Mazzaferri EL and Kloos RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463. 2001. View Article : Google Scholar : PubMed/NCBI
24	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
25	Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M and Santisteban P: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na⁺/I⁻ targeting to the membrane. Endocr Relat Cancer. 13:257–269. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al: Analysis of differ ential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 16:240–245. 2009. View Article : Google Scholar : PubMed/NCBI
27	Jovanovic L, Delahunt B, McIver B, Eberhardt NL and Grebe SK: Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol. 215:1451–1454. 2008. View Article : Google Scholar